Annovis Bio, Inc. 8-K

What Happened

• Annovis Bio, Inc. (ANVS) announced on May 20, 2026 that it entered into an underwriting agreement with Canaccord Genuity LLC to sell 7,895,000 shares of common stock and accompanying warrants in a public offering. The offering is expected to close on or about May 21, 2026 and is being made under the company’s effective Form S-3 shelf registration.

Key Details

• Gross proceeds to the company are expected to be approximately $15 million before expenses.
• Offering terms: each share is sold with nine-tenths of a warrant; the combined price per share plus nine-tenths of a warrant is $1.90.
• Warrants: immediately exercisable, expire six years from issuance, exercise price $2.25 per share; up to 7,105,500 warrant shares issuable.
• Use of proceeds: planned for continued clinical development of lead compound buntanetap (Alzheimer’s and Parkinson’s studies), and for working capital and general corporate purposes.

Why It Matters

• The financing provides near-term cash to fund Annovis’s clinical programs for buntanetap, which is central to the company’s development strategy.
• The issuance will dilute existing shareholders (new shares plus potential warrant exercises) and could increase share count if warrants are exercised at $2.25.
• Investors should watch closing confirmation, actual net proceeds, and how the company prioritizes spending between clinical development and operating needs.